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Disorders of Sex Development (DSD) are congenital anomalies in which there is a
discordance between chromosomal, genetic, gonadal, and/or internal/external genital
sex. In XY individuals, the process of fetal sex differentiation can be disrupted at
the stage of gonadal differentiation, resulting in gonadal dysgenesis, a form of early
fetal-onset primary hypogonadism characterized by insufficient androgen and anti-
Müllerian hormone (AMH) production, which leads to the development of ambiguous or
female genitalia. The process of sex differentiation can also be disrupted at the stage of
genital differentiation, due to isolated defects in androgen or AMH secretion, but not both.
These are forms of fetal-onset hypogonadism with dissociated gonadal dysfunction. In
this review, we present a perspective on impaired testicular endocrine function, i.e.,
fetal-onset male hypogonadism, resulting in incomplete virilization at birth.
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INTRODUCTION TO DISORDERS OF SEX DEVELOPMENT AND
HYPOGONADISM
Disorders of Sex Development (DSD) are congenital anomalies in which there is a discordance
between chromosomal, genetic, gonadal, and/or internal/external genital sex, as defined by the
Chicago consensus published in 2006 (1), more recently revised and endorsed by all major
societies of pediatric endocrinology (2). The etiologies and related pathogeneses of DSD can be
comprehended once the developmental physiology of fetal sex differentiation is understood, as
briefly described below. Most DSD affect the fetal endocrine and/or paracrine hormonal action
resulting in the wide spectrum of clinical and hormonal phenotype of these patients.
Hypogonadism is usually defined as the gonadal failure resulting in an impaired steroid
hormone production and deficient gamete output. Although steroids and gametes have been
recognized as gonadal products for over a century, in the last decades of the 20th century it
became evident that the somatic component of the ovaries and testes also secrete protein hormones,
like inhibins and anti-Müllerian hormone (AMH), which have a relevant role as biomarkers in
reproductive physiology from fetal life through adulthood (3, 4). Therefore, in face of the changes
occurring in the physiology of the hypothalamic-pituitary gonadal axis from fetal life to puberty,
the definition of hypogonadism should be extended to the impaired function of the ovaries or
testes, as compared to what is expected for age, that involves a decreased function of the germ
and/or somatic (Sertoli/granulosa, Leydig/theca) cell populations of the gonads, which can result
in impaired hormone secretion (estrogens, progestins, androgens, inhibins, and/or AMH) and/or
gamete production (4–6).
Grinspon et al. Male Hypogonadism and DSD
Physiology of Fetal Sex Differentiation
The process of sexual differentiation in fetal life can be
divided into three stages (Figure 1): (i) the formation of the
undifferentiated gonads and the anlagen of the genitalia, internal
(Müllerian and Wolffian ducts, urogenital sinus) and external
(genital tubercle, urethral folds, labioscrotal folds), (ii) gonadal
differentiation, and (iii) male or female differentiation of the
internal and external genitalia (8).
The initial formation of the undifferentiated gonads, the
Müllerian and Wolffian ducts, the urogenital sinus and the
undifferentiated external genitalia is identical in the XX and the
XY fetuses between the 3rd and the 5th weeks of embryonic
life (i.e., 5–7 weeks of amenorrhea). The gonadal ridges, the
urogenital sinus, and the external genitalia are bipotential, i.e.,
they can develop through either the female or the male pathways.
The internal ducts are unipotential: Müllerian ducts can give
rise only to female functional structures (the Fallopian tubes,
uterus, and upper vagina), and Wolffian ducts can differentiate
only into male structures (the epididymides, vasa deferentia, and
seminal vesicles).
Gonadal differentiation into ovaries or testes, in the 7th
week of embryonic life, depends on a complex network of
genes: the presence of the SRY gene on the Y chromosome
disrupts the balance between pro-testicular and pro-ovarian
genes, triggering testis differentiation (9–12). Subsequently, the
action of two discrete testicular hormones, AMH and androgens,
drive the differentiation of the internal ducts, urogenital sinus,
and external genitalia (Figure 2). AMH, secreted by Sertoli cells,
provokes the regression of Müllerian ducts in fetal weeks 8 and 9
FIGURE 1 | The three stages of fetal sex differentiation. During the undifferentiated stage, the mesoderm gives rise to the adreno-gonadal primordia and the Wolffian
and Müllerian ducts, whereas the ectoderm and mesoderm contribute to the formation of the genital tubercle and the urethral and labioscrotal folds. During the stage
of gonadal differentiation, the testes or ovaries develop from the gonadal ridges. During the stage of genital differentiation, the internal and external genitalia
differentiate along the male or the female pathway. Modified with permission from Rey et al. (7) © 2018 McGraw Hill Education.
(14). Androgens produced by Leydig cells induce the stabilization
and differentiation of Wolffian ducts as well as the virilization of
the urogenital sinus and the external genitalia between fetal weeks
8 and 13. These processes occurring in the first trimester of fetal
life are independent of fetal pituitary gonadotropins: basal AMH
expression is driven by a set of transcription factors (15), and
androgen production is regulated by placental hCG (16). Insulin-
like factor 3 (INSL3), produced by Ledyig cells, is involved in
testicular descent (17). Ovarian hormones have no influence on
fetal sex differentiation (18).
In the newborn, testosterone, INSL3, AMH, and inhibin B
are significantly higher in the male than in the female. During
childhood, testosterone and INSL3 levels are similar between
males and females, but AMH and inhibin B are clearly different
between sexes, with higher levels in males (19–21).
DSD: Abnormal Fetal Sex Differentiation
The process of fetal sex differentiation can be disrupted at any
of the three stages. The early morphogenesis of the reproductive
tract may fail independently of gonadal differentiation: these are
malformative, non-endocrine DSD (22) and will not be dealt with
in this review. Gonadal differentiation failure is known as gonadal
dysgenesis and results in primary hypogonadism. Testicular
dysgenesis drives to incomplete virilization, and the condition
is known as dysgenetic DSD (11, 14, 23). According to the
gene defect and probably the timing of its abnormal expression,
variable degrees of dysgenesis will result, thus eliciting variable
compromise of endocrine and paracrine secretion of androgens
andAMH. This will be reflected in different degrees of virilization
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FIGURE 2 | Male reproductive hormone levels and fetal sex differentiation. (A) Ontogeny of male reproductive hormone levels from fetal to adult periods of life. In the
early fetal stage, the initiation of testicular hormones secretion is independent of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In the second and
third trimesters, LH and FSH are the main regulators of Sertoli and Leydig cell hormone production. For ∼6 months after birth, LH, FSH, and testicular hormone
(Continued)
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FIGURE 2 | levels remain at high levels. Afterwards, in infancy and childhood, gonadotropins, testosterone (T), and insulin-like factor 3 (INSL3) levels decrease, while
those of anti- Müllerian hormone (AMH) and inhibin B continue to be high. During puberty, gonadotropins, T and INSL3 increase again to attain adult levels. AMH is
inhibited by testosterone, and inhibin B is stimulated by FSH. Reprinted, with permission, from Salonia et al. (4). © 2019 Springer Nature Limited. (B) The
undifferentiated gonad is exposed to pro-testicular and pro-ovarian factors. In the XY fetus, SRY expression regulated by MAP3K1, GATA4, SF1, and WT1 shifts the
balance toward the pro-testicular factors, like SOX9, inducing testis differentiation. Sertoli cells produce anti-Müllerian hormone (AMH), which provokes Müllerian duct
regression upon binding to its receptor AMHR2. Leydig cells express the LHCG receptor and steroidogenic proteins involved in androgen synthesis; testosterone acts
on Wolffian ducts, the urogenital sinus, and the external genitalia, either directly or after metabolization to the more potent androgen dihydrotestosterone (DHT), to
virilize them. In the XX fetus, where SRY is absent, the pro-ovarian factors WNT4, RSPO1, FOXL2, and DAX1 control the differentiation of the ovaries. The latter do not
produce androgens or AMH, which results in feminization of the internal and external genitalia. Modified with permission from Rey et al. (13) © 2016 Elsevier Saunders.
of the external genitalia and Wolffian ducts as well as in the
magnitude of regression of Müllerian structures. Conversely,
ovarian dysgenesis does not affect the development of female
genitalia. Finally, the third stage of fetal sex differentiation
can be disrupted either by a deficient production of testicular
hormones (24, 25) or an impaired action due to receptor
defects (26, 27) in the XY fetus, or to an excess androgen
exposure in the XX fetus (28–30). In this review, we will address
impaired testicular endocrine function during fetal life resulting
in incomplete virilization.
Hypogonadism: Classifications
Male hypogonadism, i.e., the impaired function of the testes as
compared to what is expected for age, may involve a decreased
hormone secretion (AMH, inhibins, and/or androgens) and/or
an impaired sperm production. It can be due to a primary
disorder or secondary to a defect in the hypothalamic-
pituitary axis, respectively resulting in primary (testicular or
hypergonadotropic) or secondary (central or hypogonadotropic)
hypogonadism (Table 1). The terms hypergonadotropic and
hypogonadotropic, extensively used in adult medicine (4), should
be applied with caution in pediatric patients (6). Indeed, although
elevated gonadotropins, especially FSH, are a typical feature of
primary hypogonadism in newborns and infants (31), normal
gonadotropin levels can occur in up to 30–70% of anorchid
boys later in childhood (32). This highlights that, throughout
childhood, the normal development of the intrinsic central
inhibitory tone exerted on GnRH pulse generator can overcome
the rise of FSH due to low serum inhibin B in circulation.
As regards to the testicular compartment that is primarily
affected, hypogonadism may present with whole gonadal
dysfunction or a dissociated, cell-specific gonadal dysfunction. In
the latter, one of the cell populations (Sertoli, Leydig, or germ
cells) is primarily disrupted while the function of the others
remains intact, at least for some time (5). Gonadal dysgenesis
is an example of primary hypogonadism with whole gonadal
dysfunction. Mutations of the FSH receptor and AMH genes
are examples of Sertoli cell-specific hypogonadism. Mutations
of the LH receptor and of steroidogenic proteins provoke
Leydig cell-specific hypogonadism. Finally, deletions of the Y
chromosome leading to azoospermia are examples of germ cell-
specific hypogonadism.
Finally, hypogonadism may be congenital or acquired during
postnatal life. The clinical presentation varies according to
the age at which hypogonadism is established (4, 33, 34);
particularly, fetal-onset hypogonadism results in DSD only when
it is established in the first trimester of gestation, as it can
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Usually, the initial diagnostic approach of patients with DSD
is based on the karyotype (35). In 46,XY individuals, the
etiology of DSD is classified into: disorders of gonadal
development (or gonadal dysgenesis), disorders of androgen
synthesis (in non-dysgenetic gonads), disorders of androgen
action, and disorders of AMH synthesis or action (resulting
in the Persistent Müllerian Duct Syndrome, PMDS) (36).
Gonadal dysgenesis and isolated disorders of androgen or
AMH synthesis represent early fetal-onset forms of primary
hypogonadism resulting in 46,XY DSD (31). Disorders of
androgen or AMH action do not initially affect testicular
hormone production and, together with non-endocrine DSD
(or unclassified disorders), will not be further discussed in
this review.
Disorders of gonadal development (or gonadal dysgenesis)
also occur in sex-chromosomal DSD (35). The most frequent
forms of sex-chromosome aneuploidies, Turner (45,X) and
Klinefelter (47,XXY) syndromes, generally do not present at
birth with genital anomalies. Therefore, they do not appear as a
differential diagnosis in the newborn. Conversely, patients with
45,X/46,XY or 46,XX/46,XY (or other mosaicisms/chimerisms)
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frequently bear diverse forms of gonadal dysgenesis (partial
testicular dysgenesis, asymmetric gonadal differentiation,
ovotestes, etc.) which lead to the existence of ambiguous
genitalia. Furthermore, ovotestes and dysgenetic testes can
develop in 46,XX fetuses, both in the presence or absence of
SRY (37).
Disorders of Gonadal Development: Early
Fetal-Onset Primary Hypogonadism With
Whole Gonadal Dysfunction
Regardless of the karyotype and the pathogenesis, gonadal
dysgenesis represents a typical form of primary hypogonadism
established in the first trimester of fetal life. Because this is the
period when internal and external genitalia are masculinized
in the presence of testicular hormones or feminized in
their absence, primary hypogonadism results in deficient
masculinization of the fetus carrying a Y chromosome (46,XY
or chimeras or mosaicisms with a Y chromosome) or in
XX fetuses carrying a translocated SRY or gene imbalances
provoking ovotesticular or dysgenetic testicular development, as
previously explained.
The impaired gonadal development is reflected in a
dysfunction of all testicular cell populations: Sertoli cells
are less numerous, thus resulting in an insufficient AMH output
leading to the existence of Müllerian remnants (Figure 3). Germ
cells are also scarce and less differentiated, with a consequently
increased risk of infertility and testicular neoplasia (38, 39).
Leydig cell number and function is also impaired, resulting in a
hypoandrogenism that leads to undervirilization of the internal
and external genitalia.
The most severe forms of dysgenesis—pure or complete
gonadal dysgenesis—present with a complete development
of the uterus and Fallopian tubes, reflecting AMH deficiency,
and absence of Wolffian remnants together with female
external genitalia, as a consequence of androgen deficiency
(Figure 4). In partial forms of gonadal dysgenesis, the
degree of virilization is variable depending on the mass of
functional testicular tissue: from micropenis, hypospadias, and
cryptorchidism with variable development of Wolffian and
Müllerian remnants to an almost female phenotype in severe
cases (40). When the condition is asymmetric—known as mixed
gonadal dysgenesis (41) or asymmetric gonadal differentiation
(42)—, a hemi-uterus and a fallopian tube exist on the side
of the streak gonad, and external genitalia may also show
asymmetric development.
Gonadal Dysgenesis in 46,XY patients
Gonadal dysgenesis may be isolated or associated with
dysmorphic features of non-reproductive organs (Table 2).
Isolated gonadal dysgenesis is caused by mutations in pro-
testicular genes. Inactivating mutations or deletions of SRY
are present in ∼15% of 46,XY females with pure gonadal
dysgenesis (Swyer syndrome) (43, 44). Non-reproductive
organs are not affected. Loss-of-function variants of MAP3K1
lead to an increased expression of pro-ovarian factors, like
β-catenin, and reduced expression of pro-testicular factors, like
SOX9/FGF9 (45). A similar pathogenesis has been proposed
FIGURE 3 | Dysgenetic DSD in 46,XY patients: early fetal-onset primary
hypogonadism with whole gonadal dysfunction. The lack of normal testis
differentiation, due to mutations of pro-testicular genes or to overexpression of
DAX1 results in gonadal dysgenesis. Consequently, the insufficient production
of androgens and anti-Müllerian hormone (AMH) results in undervirilization or
complete feminization of the internal and external genitalia. Modified with
permission from Rey et al. (13) © 2016 Elsevier Saunders.
for mutations in ZNRF3 (46). Dysgenetic DSD can also be
attributed to mutations in DHX37 (47, 48) particularly those
individuals exhibiting the embryonic testicular regression
syndrome and rearrangements involving SOX8 (49). Finally,
isolated gonadal dysgenesis was described in 46,XY females with
partial duplications of Xp21.3–p21.2, known as the DSS (dosage
sensitive sex-reversal) locus encompassing NR0B1 that encodes
DAX1; the increased expression of DAX1 is believed to impair
testis differentiation (50, 51).
Gonadal dysgenesis associated with dysmorphic features of
non-reproductive organs (Table 2) has been seen in patients with
mutations or deletions of SOX9 (52),WT1 (53),NR5A1 encoding
SF1 (54), ATRX (55), DHH (56), FOG2/ZFPM2 (57), FGFR2
(58), 9p24 encompassing DMRT1 and DMRT2 (59), HHAT (60),
ARX (61), MYRF (62), and TSPYL (63). Mutations in other
genes, like CBX2 (64), ESR2 (65),MALD1 (66, 67), STARD8 (68),
and WWOX (69), have been described in patients with gonadal
dysgenesis but their pathogenic relationship still needs to be
clearly established.
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FIGURE 4 | Development of the internal genitalia according to fetal testicular function.
In a newborn with complete (or pure) gonadal dysgenesis,
the external genitalia are typically female. There is also a normal
development of the Fallopian tubes and uterus. The phenotype is
due to a complete lack of androgen and AMH secretion. Because
of the typical female aspect, the diagnosis is not suspected
until pubertal age. Then, the absence of pubertal signs is the
main complaint. Gonadal hormones are undetectable (14) and
gonadotropins are very high in newborns. During childhood,
gonadotropin levels decrease to almost normal values by the
age of 6–9 years (70), but they increase again to extremely
high levels in pubertal age. Replacement therapy with estrogens
and progestins results in normal development of secondary sex
characteristics, and gestations have been successful after oocyte
donation (71). Gonads are characterized by the existence of
bilateral fibrous streaks, with no gonadal tissue, although in rare
cases abnormal germ cells can be observed embedded in cord-like
structures. The risk of gonadoblastoma after puberty is increased.
In patients with partial dysgenesis, the degree of virilization
of the internal and external genitalia correlates with the amount
of functional testicular tissue present during the first trimester
of intrauterine development exerting endocrine and paracrine
hormonal action. The mildest forms may present as males with
infertility. Serum levels of AMH and androgens are low for males
but above the female range, while gonadotropins are elevated,
though less than in pure gonadal dysgenesis. Although low INSL3
production might be involved in failure of testicular descent,
no information is available on serum INSL3 in patients with
dysgenetic DSD. Testes are small, have a thin albuginea with
scarce seminiferous tubules separated by wide spaces of fibrous
connective tissue. Germ cell number is significantly decreased,
and gonadal tumor risk is increased (38, 72, 73). The trend
for male assignment in these cases has increased over the
last decades (74), and the surgical repair of hypospadias and
management of tumor risk have become the main challenges
in the management (36). At the age of puberty, replacement
with testosterone leads to satisfactory development of secondary
sex characteristics and growth, but infertility is the rule in
adulthood (71).
Gonadal Dysgenesis in 46,XX Patients
As already mentioned, ovarian dysgenesis has no impact on fetal
differentiation of the female genitalia; these patients do not seek
medical assistance until the age of puberty, when the lack of
ovarian steroids results in delayed puberty. These disorders will
not be discussed amongst the DSD due to fetal hypogonadism
addressed in this review. Congenital adrenal hyperplasia,
aromatase deficiency, and other conditions characterized by fetal
virilization not due to fetal-onset hypogonadism are also out of
the scope of this review.
Disorders of gonadal differentiation leading to the
development of testicular tissue and ambiguous or male genitalia
may occur in 46,XX individuals. In the originally described “XX
male” (75), testes differentiate almost normally—only minor
signs of dysgenesis are present, characterized by lower numbers
of germ cells (76)—and the patients are fully virilized. These
patients usually seek medical attention in adulthood owing to
infertility (34). This is a typical case of a cell-specific dissociated
hypogonadism, where only the germ cell population is initially
affected: spermatogenesis is disturbed by the presence of two
X chromosomes and the lack of Y-chromosome genes that are
essential for germ cell development. Approximately 90% of XX
males are SRY-positive, i.e., they bear part of the short arm of
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Campomelic dysplasia: bowing of long bones,
hip dislocation, scapula hypoplasia, small
thoracic cage, micrognathia, macrocephaly,
low-set ears, flat nasal bridge, and cardiac and
renal defects
SOX9 17q24.3
Denys-Drash syndrome: nephropathy and
Wilms tumor
WT1 11p13
Frasier syndrome: nephropathy and
gonadoblastoma
Adrenal insufficiency NR5A1 9q33.3
ATRX syndrome: α-thalassemia and mental
retardation
ATRX Xq21.1
Minifascicular neuropathy DHH 12q13.12




Microcephaly, mental retardation, short stature,
and/or bronchial or digestive malformations
DMRT1/DMRT2 9p24.3
Chondrodysplasia, cerebellar hypoplasia, and
coloboma of the optic disks
HHAT 1q32.2
Lissencephaly and epilepsy ARX Xp21.3
Cardiac malformations MYRF 11q12.2
Sudden death TSPYL 6q22.1
the Y chromosome translocated onto the X chromosome or an
autosome (77).
SRY-negative cases have been intriguing for decades (78), until
the importance of a balance between pro-testicular and pro-
ovarian genes was apprehended. The development of testicular
tissue has been attributed to: (i) overexpression of pro-testicular
genes, (ii) insufficient expression of pro-ovarian genes, and (iii)
mixed or unknown pathogenic mechanisms (37).
Overexpression of testicular factors was initially described
in patients bearing duplications of the SOX9 gene or
duplications/triplications of its regulatory sequences (79–
85), and subsequently found in individuals with duplications or
rearrangements of the SOX3 gene (84, 86–88) or its regulatory
sequences (89, 90), and duplications of SOX10 (91–95) or
FGF9 (96). Insufficient expression of pro-ovarian genes has
been proposed as the underlying pathogenesis in patients with
loss-of-function mutations or deletions of RSPO1 (97–100) or
WNT4 (101). More recently, 46,XX testicular or ovotesticular
DSD has been attributed to mutations in NR5A1, encoding
SF1 (102–107), WT1 (108) and NR2F2, encoding COUP-TF2
(109, 110).
The resulting phenotype can be either testicular or
ovotesticular DSD; the testicular tissue usually shows signs
of typical dysgenesis, justifying a primary hypogonadism with
whole gonadal dysfunction. External genitalia are ambiguous,
reflecting insufficient androgen levels to fully virilize the fetus,
and Müllerian remnants may be present, indicating deficient
AMH production.
Sex assignment in these cases follows the general suggestions
for DSD (2). In patients raised as boys, there is a need for ovarian
tissue removal, if present, before the age of puberty to prevent
potential complications of cystic follicle development and to
avoid gynecomastia due to estrogen secretion (111). The risk of
tumor development in the testicular tissue seems to be low, likely
due to the absence of Y-chromosome peri-centromeric sequences
(72). In patients with ambiguous genitalia and a diagnosis of
ovotesticular DSD, attention should be driven to the fact that the
ovarian tissue may produce oocytes after pubertal development,
which raises the possibility of fertility (112). In these cases,
assignment to the female gender may be preferred, and special
care should be taken during testicular tissue removal to preserve
the ovarian tissue.
Gonadal Dysgenesis in Sex-Chromosome DSD
The lack of the short arm of the Y chromosome, where SRY
maps, is responsible for gonadal dysgenesis in patients with
sex-chromosome mosaicisms or chimeras. It is noteworthy
that the frequent sex-chromosome aneuploidies observed in
patients with Klinefelter syndrome (47,XXY and variants) and
in triple X syndrome (47,XXX and variants) most usually
present typical genitalia at birth and do not represent a
differential diagnosis of the conditions discussed in this review.
Several different karyotypes have been described in patients
with sex-chromosome DSD presenting with ambiguous genitalia.
The most prevalent is 45,X/46,XY, which is usually—though
not always—associated with asymmetric gonadal differentiation
(41, 42, 73). 46,XX/46,XY chimeras usually present with
ovotesticular DSD.
Disorders of Testicular Hormone Synthesis:
Early Fetal-Onset Primary Hypogonadism
With Dissociated Dysfunction
Congenital specific disorders of androgen or AMH synthesis are
examples of non-dysgenetic, early-onset, primary hypogonadism
characterized by a cell-specific testicular dysfunction in 46,XY
patients. The main feature is that only Leydig cell function
is impaired in one case and exclusively Sertoli cell secretion
is affected in the other, leading to specific clinical and
biochemical presentations.
46,XY DSD Due to Disorders of Androgen Synthesis
The main sources of androgens are the gonads and the
adrenals. There are steps of steroidogenesis that are common
to the testis and the adrenal cortex, and others are specific
to the gonads (Figure 5) (24, 29). Disorders of androgen
synthesis represent a “dissociated” or “cell-specific” fetal-
onset primary hypogonadism, characterized by impaired
Leydig cell, but normal Sertoli cell, function. Testosterone
levels are low, but serum AMH is within the normal male
range or elevated (113), and Müllerian derivatives are absent
Frontiers in Endocrinology | www.frontiersin.org 7 April 2020 | Volume 11 | Article 211
Grinspon et al. Male Hypogonadism and DSD
FIGURE 5 | Steroidogenesis. The steroidogenic pathway occurring in testicular Leydig cells is schematically shown in the box. Steroidogenic steps taking place in the
adrenals, placenta, and ovaries are outside the box. Modified with permission from Rey et al. (14) © 2010 Elsevier Ltd.
(Figure 6). Steroidogenic defects, like that of insufficient
testosterone conversion to dihydrotestosterone (DHT)
occurring locally in the end-organ due to mutations in the
gene encoding 5α-reductase type 2, will not be discussed in
this review, since they do not represent a form of impaired
gonadal function.
Disorders of androgen synthesis affecting the testes and the
adrenals
Cholesterol is the initial substrate for steroid synthesis.
Smith-Lemli-Opitz Syndrome (SLOS) results from a defect
in dehydrocholesterol reductase (DHCR), involved in the
last step of cholesterol synthesis. Cholesterol also plays a
major role in the formation of the nervous system, face,
and limbs; therefore, patients with SLOS present with DSD
associated with polymalformations including microcephaly,
facial malformations, growth retardation and congenital heart
defects (114). Clinical diagnosis of SLOS is suspected in patients
with elevated 7–dehydrocholesterol and low cholesterol.
The first step of gonadal and adrenal steroidogenesis
is cholesterol transfer from the cytoplasm into the inner
mitochondrial membrane (Figure 5), under control of the
steroidogenic acute regulatory protein (StAR). Defects in the
STAR gene lead to lipoid congenital adrenal hyperplasia. Most
46,XY newborns present with female external genitalia and
severe glucocorticoid and mineralocorticoid deficiency. Milder
forms have been reported with ambiguous or male genitalia.
All steroids are low and no response is observed after hCG
and ACTH stimulation. There is massive adrenal enlargement,
due to accumulation of cholesterol esters in the adrenal
cortex (115).
Subsequently, cytochrome P450 cholesterol side-chain
cleavage enzyme cytochrome P450 (P450scc) catalyzes the
synthesis of pregnenolone. P450scc deficiency, due to mutations
in CYP11A1, also results in very low steroid levels but without
adrenal enlargement. Most 46,XY patients are born with
female external genitalia, but partial deficiencies present with
ambiguous genitalia (115, 116).
Cytochrome P450c17 has two enzymatic activities
(Figure 5): 17α-hydroxylase, which hydroxylates pregnenolone
or progesterone into 17α-hydroxypregnenolone or 17α-
hydroxyprogesterone (17-OHP), and 17,20-lyase, required for
the synthesis of dehydroepiandrosterone (DHEA) and 14-
androstenedione. Mutations in CYP17A1, encoding P450c17,
may induce a combined deficiency of 17α-hydroxylase and 17,20-
lyase, but isolated 17,20-lyase deficiency has also been described.
The 46,XY newborns are undervirilized. Progesterone and 17-
OHP are high in serum whereas DHEA, 14-androstenedione,
and testosterone are low. Combined 17α-hydroxylase/17,20-
lyase deficiency leads to hypertension and hypokalemia due to
the accumulation of deoxycorticosterone and corticosterone.
In isolated 17,20-lyase deficiency, testicular, but not adrenal,
function is impaired (116, 117).
Cytochrome b5 enhances 17,20-lyase activity of P450c17
but does not modify 17-hydroxylase activity. It also
reduces methemoglobin (ferric hemoglobin) to normal
hemoglobin (ferrous hemoglobin). Mutations in CYB5A
result in 46,XY DSD with impaired 17,20-lyase activity and
methemoglobinemia (116).
P450 oxidoreductase (POR) is essential for the catalytic
activity of P450c17 (preferentially its 17,20-lyase activity),
21-hydroxylase and aromatase (116, 118). XY newborns
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with POR mutations are undervirilized but present mild
signs of congenital adrenal hyperplasia (e.g., elevated 17-
OHP), and their mothers virilize due to impaired placental
aromatase. Severe mutations lead to the Antley-Bixler syndrome,
characterized by craniosynostosis, fusion of long bones, midface
hypoplasia, and choanal stenosis. Laboratory findings reflect the
combined deficiencies of 17α-hydroxylase and 21-hydroxylase:
elevated serum progesterone and 17-OHP but low DHEA
and androstenedione.
3β-hydroxysteroid dehydrogenase (HSD) type 2 catalyzes
the conversion of 15- to 14-steroids (pregnenolone to
progesterone, 17α-hydroxypregnenolone to 17-OHP, DHEA to
androstenedione, and androstenediol to testosterone; Figure 5).
Mutations in HSD3B2 leads to 3β-HSD type 2 deficiency,
characterized by ambiguous genitalia and variable adrenal
impairment (116). Laboratory findings are characterized by
an elevated 15/14 steroids ratio, particularly after ACTH or
hCG stimulation.
FIGURE 6 | DSD due to steroidogenic defects in 46,XY patients: early
fetal-onset primary hypogonadism with Leydig cell-specific dysfunction. The
lack of Leydig cell differentiation, due to mutations in the LHCGR gene, or in
steroidogenic proteins leads to insufficient androgen production by the testes
resulting in undervirilization or complete feminization of the external genitalia. In
these patients, there is no uterus or Fallopian tubes because anti-Müllerian
hormone (AMH) is produced by Sertoli cells. Modified with permission from
Rey et al. (13) © 2016 Elsevier Saunders.
Disorders of androgen synthesis specifically affecting the
testes
LH and hCG bind to the same receptor on the Leydig cell
membrane to induce their typical steroidogenic phenotype.
Inactivating mutations in the LHCGR gene lead to Leydig
cell aplasia or hypoplasia resulting in various degrees
of undervirilization: from micropenis, hypospadias, and
cryptorchidism to female external genitalia. All androgen levels
are low in basal conditions and after hCG stimulation, but
adrenal steroid response to ACTH is normal (119).
The enzyme 17β-HSD type 3 converts 14-androstenedione
to testosterone in the testes (Figure 5) (24, 116). HSD17B3
gene mutations lead to 46,XY DSD characterized by a
female or ambiguous external genital phenotype and
unaffected adrenal function. Virilization may occur at
pubertal age owing to androgen synthesis by other
isoforms, like that encoded by HSD17B5 (also called
AKR1C3) involved in the “backdoor” steroidogenic pathway
(116). Laboratory findings are characterized by elevated
14-androstenedione and low testosterone after hCG
stimulation (24).
FIGURE 7 | DSD due to anti-Müllerian hormone (AMH) deficiency in 46,XY
patients: early fetal-onset primary hypogonadism with Sertoli cell-specific
dysfunction. Mutations of the AMH gene are responsible for the persistence of
the uterus and Fallopian tubes, a condition known as Persistent Müllerian Duct
Syndrome (PMDS), in otherwise normally virilized newborns. Modified with
permission from Rey et al. (13) © 2016 Elsevier Saunders.
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46,XY DSD Due to Disorders of AMH Synthesis
Defects in Sertoli cell AMH secretion, due to mutations
in the AMH gene, are a typical form of “dissociated” or
“cell-specific” fetal-onset primary hypogonadism, characterized
by impaired Sertoli cell, but normal Leydig cell, function
(Figure 7). The resulting disorder is known as the persistent
Müllerian duct syndrome (PMDS), which is characterized by
the presence of the uterus and Fallopian tubes in an otherwise
normally virilized newborn (27). The existence of ambiguous
external genitalia, which reflects a concomitant defect in
androgen synthesis, rules out the diagnosis of PMDS. Clinical
manifestations are cryptorchidism with or without inguinal
hernia, and the diagnosis is not suspected until Müllerian
derivatives are unexpectedly found at surgery. Mutations in
the AMH gene explain ∼45% of PMDS patients. Serum
testosterone and gonadotropins are in the male range. AMH
FIGURE 8 | DSD and fetal-onset male hypogonadism. 46,XY DSD may result from various forms of primary fetal-onset male hypogonadism, or from defects in
hormone action in target organs (AIS: androgen insensitivity syndrome, or 5α-reductase deficiency), without hypogonadism. In 46,XX individuals with testicular
differentiation, partial virilization results from impaired testicular function; in completely virilized newborns, Leydig and Sertoli cell function is preserved and only germ
cell development is impaired; however, the most frequent situation of XX virilization results from dysfunction of the adrenals (e.g., congenital adrenal hyperplasia, CAH)
or the placenta (aromatase deficiency). Chromosomal DSD with 45,X/46,XY or 46,XX/46,XY karyotypes, testicular tissue is characterized by impaired function of all
cell populations, as shown by the existence of testosterone and AMH levels that are below the male range. AIS, androgen insensitivity syndrome; CAH, congenital
adrenal hyperplasia; Def., deficiency; Malformative, anatomical malformation of the genitalia not due to hormonal disorders; PMDS, persistent Müllerian duct
syndrome, due to specific AMH defects, < or > female or male: below or above normal female or male range.
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is undetectable in patients with AMH mutations. In patients
with PMDS due to AMH receptor defects, testicular function
is not affected and AMH levels are within the male range (25).
Malignant tumors of the testes occur in ∼1/3 of adults with the
disorder, while malignancies of the Müllerian derivatives are less
frequent (27).
EARLY FETAL-ONSET CENTRAL
HYPOGONADISM DOES NOT LEAD TO
DSD
The GnRH neurons derive from cells present in the nasal
placode (120), which migrate together with olfactory axons
through the cribriform plate and arrive in the developing
forebrain in the 9th−10th weeks. The pituitary develops from
the Rathke’s pouch, and functional gonadotropes secrete LH
from fetal week 12 (121), when sex differentiation is almost
complete. As mentioned, Leydig cells secrete androgens
driven by hCG rather by pituitary LH during the period of
sex differentiation. This explains why 46,XY fetuses virilize
in spite of complete absence of gonadotropin secretion
in congenital central (hypogonadotropic) hypogonadism.
Because testicular androgen synthesis is dependent on
fetal LH during the second and third trimesters, these
patients present with micropenis and cryptorchidism at
birth (31).
CONCLUDING REMARKS
In patients with a Y chromosome (46,XY, 45,X/46,XY, or
variants), DSD usually results from testicular dysgenesis, an
early fetal-onset hypogonadism characterized by whole gonadal
dysfunction presenting with serum levels of testosterone
and AMH that are below the male range (Figure 8). In
46,XY individuals, DSD may result from isolated Leydig cell
dysfunction; this dissociated form of fetal-onset hypogonadism
is characterized by androgen levels below the male range and
AMH within the male range. When there is an isolated Sertoli
cell dysfunction, AMH is low while testosterone is within the
male range. If both testosterone and AMH are within the male
range, DSD is not due to fetal-onset hypogonadism, but rather
to a defect in the target organ, e.g., androgen insensitivity or
5α-reductase deficiency, or to an anatomical malformation. In
46,XX newborns with ambiguous or male genitalia, testicular
or ovotesticular DSD may be the underlying cause; Sertoli
and Leydig cell populations may be affected, resulting in
undervirilization but they may be functionally normal, like in the
XX male presenting with testosterone and AMH levels within
the male range. In newborns with androgen levels above but
AMH within the female range, virilization is not related to
hypogonadal states but rather to adrenal or placental dysfunction.
In chimeric forms of DSD, e.g., 46,XX/46,XY or variants,
ovotesticular differentiation usually occurs, characterized by
androgen and AMH levels that are above the female but below
the male range, indicating that there is a whole testicular tissue
dysfunction. All these are primary forms of fetal hypogonadism.
Fetal-onset central hypogonadism usually leads to micropenis
or cryptorchidism, reflecting insufficient androgen production
in the second half of intrauterine life, but does not result in
ambiguous genitalia.
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